Related Experiment Video
Updated: Apr 1, 2026
03:37
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
5.3K
Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label,
Jingyuan Zhao1, Xueqin Song2, Xiaoqing Ai1
1Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China; Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, Xinxiang, China.
Plos One
|October 9, 2015
Summary
Adjunctive aripiprazole effectively reduced prolactin levels and improved negative symptoms in schizophrenia patients experiencing risperidone-induced hyperprolactinemia. This treatment demonstrated safety and efficacy over 8 weeks.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Risperidone, an antipsychotic, can cause hyperprolactinemia, leading to adverse effects.
- Hyperprolactinemia in schizophrenia patients requires effective management strategies.
Purpose of the Study:
- To assess the efficacy and safety of adding aripiprazole to risperidone treatment.
- To evaluate the impact of adjunctive aripiprazole on prolactin levels and schizophrenia symptoms.
Main Methods:
- A randomized controlled trial involving 113 schizophrenia patients with risperidone-induced hyperprolactinemia.
- Patients received either risperidone plus aripiprazole (10 mg/day) or risperidone alone for 8 weeks.
- Symptom severity (PANSS) and prolactin levels were monitored regularly.
Main Results:
- Adjunctive aripiprazole significantly decreased total and negative PANSS scores compared to the control group.
- Serum prolactin levels were significantly reduced in the aripiprazole group from week 2 onwards.
- No significant differences in most metabolic parameters or adverse reactions were observed between groups.
Conclusions:
- Adjunctive aripiprazole is a potentially beneficial treatment for managing risperidone-induced hyperprolactinemia in schizophrenia.
- This approach may improve negative symptoms and normalize prolactin levels without compromising safety.
